259 related articles for article (PubMed ID: 25432949)
1. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
[No Abstract] [Full Text] [Related]
2. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MV; Matta AP; Mendes MF; Siquineli F
Headache; 2015 Apr; 55(4):578-9. PubMed ID: 25754576
[No Abstract] [Full Text] [Related]
3. Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
Forrestel AK; Modi BG; Longworth S; Wilck MB; Micheletti RG
JAMA Neurol; 2016 Mar; 73(3):355-6. PubMed ID: 26751160
[No Abstract] [Full Text] [Related]
4. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
5. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
Giovannoni G; de Jong B; Derfuss T; Izquierdo G; Mazibrada G; Molyneux P; Nicholas R; Overell J; Ziemssen T; Juliusson G
Mult Scler Relat Disord; 2015 Jan; 4(1):83-4. PubMed ID: 25787058
[No Abstract] [Full Text] [Related]
6. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
7. [Fingolimod].
Hashi Y; Kondo T
Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
[No Abstract] [Full Text] [Related]
8. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
Thoo S; Cugati S; Lee A; Chen C
Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
[TBL] [Abstract][Full Text] [Related]
10. Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
Kawiorski MM; Viedma-Guiard E; Costa-Frossard L; Corral I
Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):138-9. PubMed ID: 24958672
[No Abstract] [Full Text] [Related]
11. Herpes zoster: a potential risk associated with fingolimod treatment.
Mayor Ibarguren A; Gómez Fernández C; Tallón Barranco A; Fernández Fournier M; González Ramos J; Romero Gómez MP; Herranz Pinto P
Int J Dermatol; 2015 Sep; 54(9):e373-5. PubMed ID: 26173466
[No Abstract] [Full Text] [Related]
12. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
[No Abstract] [Full Text] [Related]
13. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Cheraghmakani H; Nasehi MM; Baghbanian SM
Mult Scler Relat Disord; 2019 Aug; 33():116-120. PubMed ID: 31185372
[TBL] [Abstract][Full Text] [Related]
15. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C
Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070
[TBL] [Abstract][Full Text] [Related]
16. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
[No Abstract] [Full Text] [Related]
17. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
18. [A case of multiple sclerosis who relapsed early after fingolimod therapy introduced].
Endo H; Chihara N; Sekiguchi M D K; Kowa H; Kanda F; Toda T
Rinsho Shinkeigaku; 2015; 55(6):417-20. PubMed ID: 26103815
[TBL] [Abstract][Full Text] [Related]
19. Famous.
Kim MJ; Bhatti MT; Costello F
Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
[TBL] [Abstract][Full Text] [Related]
20. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
